- Home
- OGE vs MDGL Comparison
OGE vs MDGL Comparison
Compare OGE & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGE
- MDGL
- Stock Information
- Founded
- OGE 1902
- MDGL 2011
- Country
- OGE United States
- MDGL United States
- Employees
- OGE N/A
- MDGL N/A
- Industry
- OGE Electric Utilities: Central
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- OGE Utilities
- MDGL Health Care
- Exchange
- OGE Nasdaq
- MDGL Nasdaq
- Market Cap
- OGE 8.3B
- MDGL 7.4B
- IPO Year
- OGE N/A
- MDGL N/A
- Fundamental
- Price
- OGE $41.01
- MDGL $308.44
- Analyst Decision
- OGE Buy
- MDGL Buy
- Analyst Count
- OGE 6
- MDGL 14
- Target Price
- OGE $39.40
- MDGL $347.33
- AVG Volume (30 Days)
- OGE 1.1M
- MDGL 355.8K
- Earning Date
- OGE 11-05-2024
- MDGL 10-31-2024
- Dividend Yield
- OGE 4.11%
- MDGL N/A
- EPS Growth
- OGE N/A
- MDGL N/A
- EPS
- OGE 1.93
- MDGL N/A
- Revenue
- OGE $2,791,500,000.00
- MDGL $76,813,000.00
- Revenue This Year
- OGE $6.72
- MDGL N/A
- Revenue Next Year
- OGE $5.36
- MDGL $194.49
- P/E Ratio
- OGE $21.24
- MDGL N/A
- Revenue Growth
- OGE N/A
- MDGL N/A
- 52 Week Low
- OGE $32.06
- MDGL $168.25
- 52 Week High
- OGE $44.41
- MDGL $368.29
- Technical
- Relative Strength Index (RSI)
- OGE 38.48
- MDGL 51.11
- Support Level
- OGE $40.50
- MDGL $289.80
- Resistance Level
- OGE $42.46
- MDGL $315.09
- Average True Range (ATR)
- OGE 0.65
- MDGL 12.44
- MACD
- OGE -0.27
- MDGL -4.11
- Stochastic Oscillator
- OGE 17.65
- MDGL 48.58
About OGE OGE Energy Corp
OGE Energy is a holding company for Oklahoma Gas & Electric, a regulated utility with electricity generation, transmission, and distribution to 900,000 customers in Oklahoma and western Arkansas. In December 2021, OGE divested its 25.5% stake in Enable Midstream Partners, an oil and gas services company it created in 2013 through a unit exchange merger with Energy Transfer. OGE sold its 95.4 million limited partner units of Energy Transfer throughout 2022. OGE sold its retail gas business in 1928 and no longer has any gas operations.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.